The primary objective of the study is to collect epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity and to correlate EGFR mutation status with clinico-pathological characteristics (e.g. smoking status, sex, histology, etc). In particular, the study will aim to determine the frequency of EGFR M+ lung cancers in patients with clinico-pathological characteristics that are not commonly associated with EGFR mutation positivity (i.e., smokers, men, and non-adenocarcinoma).
An NIS Registry for the Epidemiological and Scientific evaluation of EGFR mutation status in patients with newly diagnosed locally advanced or metastatic NSCLC (stage IIIB/IV non-small cell lung cancer)
Study Type
OBSERVATIONAL
Enrollment
4,243
Research Site
Aachen, Germany
Research Site
Amberg, Germany
Research Site
Ansbach, Germany
Research Site
Aschaffenburg, Germany
Research Site
Augsburg, Germany
Research Site
Bad Berka, Germany
Research Site
Ballenstedt, Germany
Research Site
Bamberg, Germany
Research Site
Bayreuth, Germany
Research Site
Berlin, Germany
...and 108 more locations
The primary objective of the study is to collect epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity and to correlate EGFR mutation status with clinico-pathological characteristics
Time frame: Days 1-10
To collect real-life clinical outcome data in all EGFR M+ patients up to and including progression.To collect real-life pharmacoeconomic data (resource use) associated with the diagnosis and treatment of EGFR M+ patients.
Time frame: Study Days 21-30
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.